



Ningbo Zheng, PhD

Postdoc

University of Houston

*T-Cell Dysfunction Associated With The LRRK2 Mutation In
The Pathogenesis Of Parkinson's Disease*

Ningbo Zheng, received her PhD at Tianjin Medical University, Tianjin, China. In Jan 2020, she started her postdoctoral fellowship, concentrating on T cell immunotherapy against tumors, including using CAR-T and a new tumor-specific Th9 cell-paradigm to eradicate advanced tumors. She joined Dr. Peng's lab in Feb 2022, working on the LRRK2-mediated T cell dysfunction in Parkinson's disease (PD) project. Specifically, she aims to determine whether the LRRK2 G2019S mutation contributes to the pathogenesis of PD by influencing T cell functionality.